PDCD1 and hereditary clear cell renal cell carcinoma: A meta-analysis that investigated CIP incidence among clinical trial participants with melanoma, NSCLC, or renal cell carcinoma reported an overall incidence of 2.7% during PD-1 inhibitor therapy and an incidence of 0.8% for grades three and higher [6].